Business Context and Reporting Period
This Form 6-K filing by Sanofi-Aventis covers the month of January 2005. The report serves to disclose a material corporate event rather than periodic financial results.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a regulatory notification of a specific event and does not contain financial statements.
Material Changes
The primary material change reported is the receipt of United States Food and Drug Administration (US FDA) approval for the Menactra® Vaccine. This approval was announced via a press release dated January 17, 2005, and incorporated as Exhibit 99.1.
Guidance, Outlook, and Risks
The filing does not contain financial guidance, management commentary on future performance, or a discussion of risks and contingencies beyond the regulatory approval event. No unusual items were disclosed in the text of this specific filing.
Investor Verification Points
- Verify the commercial launch timeline and market strategy for Menactra® following FDA approval.
- Review the full text of the January 17, 2005 press release (Exhibit 99.1) for details on the vaccine's indications and competitive landscape.
- Confirm the impact of this approval on Sanofi-Aventis's vaccine portfolio revenue in subsequent quarterly reports.